As March approaches, the FDA is expected to announce key decisions on the New Drug Applications for Reproxalap, Linerixibat, Kresladi, and LNTH-2501. For Kresladi, this marks a second bid for approval, while Reproxalap is making its third attempt. The path to FDA approval is often challenging for many drug candidates.
Meanwhile, approved therapies Sotyktu and Imcivree await decisions on label expansions, adding further regulatory catalysts to the month.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.